Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Lymphoma patients needed for trial
Six months of free remission monitoring to aid study

Axiom Veterinary Laboratories are looking for dogs that have been diagnosed with lymphoma in order to validate a test.

The test has been developed by Petscreen, to find acute phase proteins for monitoring remission in canine lymphoma patients.

Axiom will be performing a trial of Petscreen's work, to assess its ability to detect when a lymphoma patient is in and out of remission. If validated, vets old be provided with a method of identifying relapse earlier than palpation alone, which could potentially extend patient's lives.

To be involved in the trial, Axiom are looking for dogs that have cytologically or histologically confirmed lymphoma, diagnosed within two weeks of the first serum sample being taken. Preferably, they would not have received any treatment, including steroids.

The process will involve testing a serum sample taken from the patient at week zero, followed by monthly tests to monitor the patient's status, therefore, offering 100 patients six months of free remission monitoring.

If you would like a discussion, or have any patients you would like to put forward for the trial, please contact Emma Dewhurst of Axiom on 01626 355655 or via email.

Click here to find out more about Petscreen's work on the development so far.

Become a member or log in to add this story to your CPD history

Annual submission deadline small pet animal exemptions

News Story 1
 Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.

Submitting this annual return ensures continued compliance with regulatory requirements for products marketed without a full Marketing Authorisation. The exemption specifically applies to products intended for animals, cage birds, terrarium animals, small rodents, ferrets and rabbits.

For further details and submission guidelines, visit the gov.uk website.  

Click here for more...
News Shorts
BVA urges 'continued vigilance' over bluetongue

The British Veterinary Association (BVA) has urged vigilance following a concerning rise in Bluetongue (BTV) cases in sheep and cattle.

In a recent statement, the BVA noted that members are reporting more severe clinical signs and higher mortality rates than in previous years.

'We know that farm vets are working hard to support farmers and animals affected by this outbreak, during what is an extremely difficult time for all involved,' they stated. 'Continued vigilance to identify disease early is vital and vaccination remains the best way of protecting animals from this disease.'